Strange: Bullish FATE Analysts Actually See -25.48% Downside
December 31, 2020 at 08:29 AM EST
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Fate Therapeutics Inc (FATE). The average 12-month price target for FATE — averaging the work of 13 analysts — reveals an average price target of $69.77/share..